These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2317562)

  • 1. Shed tumor gangliosides and progression of human neuroblastoma.
    Valentino L; Moss T; Olson E; Wang HJ; Elashoff R; Ladisch S
    Blood; 1990 Apr; 75(7):1564-7. PubMed ID: 2317562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ganglioside G
    Balis FM; Busch CM; Desai AV; Hibbitts E; Naranjo A; Bagatell R; Irwin M; Fox E
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28031. PubMed ID: 31612589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shedding of GD2 ganglioside by human neuroblastoma.
    Ladisch S; Wu ZL; Feig S; Ulsh L; Schwartz E; Floutsis G; Wiley F; Lenarsky C; Seeger R
    Int J Cancer; 1987 Jan; 39(1):73-6. PubMed ID: 3539825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients.
    Czaplicki D; Horwacik I; Kowalczyk A; Wieczorek A; Bolek-Marzec K; Balwierz W; Kozik A; Rokita H
    Acta Biochim Pol; 2009; 56(3):423-31. PubMed ID: 19724779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shedding of human neuroblastoma gangliosides.
    Li RX; Ladisch S
    Biochim Biophys Acta; 1991 Apr; 1083(1):57-64. PubMed ID: 2031938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent reference intervals in children for the disialoganglioside, G
    Busch CM; Balis FM
    Clin Biochem; 2022 Mar; 101():1-4. PubMed ID: 34929151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2.
    Li R; Gage D; McKallip R; Ladisch S
    Glycoconj J; 1996 Jun; 13(3):385-9. PubMed ID: 8781969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma cells can be classified according to glycosphingolipid expression profiles identified by liquid chromatography-tandem mass spectrometry.
    Kaneko T; Okita H; Nakajima H; Iijima K; Ogasawara N; Miyagawa Y; Katagiri YU; Nakagawa A; Kiyokawa N; Sato T; Fujimoto J
    Int J Oncol; 2010 Nov; 37(5):1279-88. PubMed ID: 20878075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
    Perez CA; Ravindranath MH; Soh D; Gonzales A; Ye W; Morton DL
    Cancer J; 2002; 8(5):384-94. PubMed ID: 12416896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of shed human tumor gangliosides: association with serum lipoproteins.
    Valentino LA; Ladisch S
    Cancer Res; 1992 Feb; 52(4):810-4. PubMed ID: 1737341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma.
    Ladisch S; Wu ZL
    Lancet; 1985 Jan; 1(8421):136-8. PubMed ID: 2857215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of GD2 ganglioside by untreated primary human neuroblastomas.
    Wu ZL; Schwartz E; Seeger R; Ladisch S
    Cancer Res; 1986 Jan; 46(1):440-3. PubMed ID: 3940209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of gangliotriaose-series glycosphingolipids in serum of cord blood and patients with neuroblastoma by a sensitive TLC/enzyme-immunostaining method.
    Yamanaka T; Hirabayashi Y; Hirota M; Kaneko M; Matsumoto M; Kobayashi N
    Biochim Biophys Acta; 1987 Jul; 920(2):181-4. PubMed ID: 3300782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroblastomas of infancy exhibit a characteristic ganglioside pattern.
    Kaucic K; Etue N; LaFleur B; Woods W; Ladisch S
    Cancer; 2001 Feb; 91(4):785-93. PubMed ID: 11241247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
    Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
    Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor gangliosides enhance platelet activation.
    Valentino LA; Ladisch S
    Blood; 1994 May; 83(10):2872-7. PubMed ID: 8180382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding of GD2 ganglioside in patients with retinoblastoma.
    Portoukalian J; David MJ; Gain P; Richard M
    Int J Cancer; 1993 Apr; 53(6):948-51. PubMed ID: 8473052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low complex ganglioside expression characterizes human neuroblastoma cell lines.
    Hettmer S; Ladisch S; Kaucic K
    Cancer Lett; 2005 Jul; 225(1):141-9. PubMed ID: 15922866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gangliosides in neuroblastomas.
    Schengrund CL; Shochat SJ
    Neurochem Pathol; 1988 Jun; 8(3):189-202. PubMed ID: 3075728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.